CD8A and neoplasm: In contrast, combination of M002 and anti-PD1 immunotherapies resulted in a significant increase in CD8+ localization to the tumor microenvironment in both in vivo and ex vivo imaging, providing supportive evidence on the immunological benefit of combination oHSV and ICI previously reported in literature 14.